GT
LCTX icon

Glenmede Trust’s Lineage Cell Therapeutics LCTX Stock Holding History

Glenmede Trust’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-2
Closed – – 2543
2020
Q1 		$0 Hold
2
– – ﹤0.01% 3036
2019
Q4 		$0 Hold
2
– – ﹤0.01% 3080
2019
Q3 		$0 Hold
2
– – ﹤0.01% 3069
2019
Q2 		$0 Hold
2
– – ﹤0.01% 3125
2019
Q1 		$0 Buy
+2
New +$2 ﹤0.01% 3125
2015
Q3 		– Sell
-1
Closed – – 2773
2015
Q2 		$0 Hold
1
– – ﹤0.01% 2732
2015
Q1 		$0 Buy
+1
New +$3 ﹤0.01% 2504

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Glenmede Trust's LCTX Position: Q2 2020 in Review

Glenmede Trust sold out of Lineage Cell Therapeutics (LCTX) in Q2 2020, closing a stake of 2 shares.

Glenmede Trust first reported a position in LCTX in Q1 2015 and held it in 7 quarters. The position peaked at $0 in Q1 2020. 94 funds tracked by Wall St. Rank hold LCTX as of Q2 2020.

  • Glenmede Trust reported no remaining Lineage Cell Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Glenmede Trust sold 2 Lineage Cell Therapeutics shares in Q2 2020.
  • Glenmede Trust first reported a position in Lineage Cell Therapeutics in Q1 2015 and held it in 7 quarters.
  • Glenmede Trust's Lineage Cell Therapeutics position peaked at $0 in Q1 2020.
  • 94 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2020.

Based on Glenmede Trust's 13F filing for Q2 2020, filed 14 Aug 2020.